Kura Oncology, Inc. (KURA) Stake Boosted by Nationwide Fund Advisors
Nationwide Fund Advisors lifted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 66.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 25,758 shares of the company’s stock after purchasing an additional 10,258 shares during the quarter. Nationwide Fund Advisors owned about 0.13% of Kura Oncology worth $240,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of KURA. State of Wisconsin Investment Board acquired a new stake in Kura Oncology in the 2nd quarter valued at about $102,000. Rhumbline Advisers acquired a new stake in Kura Oncology in the 2nd quarter valued at about $131,000. Schwab Charles Investment Management Inc. acquired a new stake in Kura Oncology in the 2nd quarter valued at about $226,000. Teachers Advisors LLC acquired a new stake in Kura Oncology in the 2nd quarter valued at about $256,000. Finally, Bank of New York Mellon Corp acquired a new stake in Kura Oncology in the 2nd quarter valued at about $291,000. 39.11% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Kura Oncology, Inc. (KURA) Stake Boosted by Nationwide Fund Advisors” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/14/kura-oncology-inc-kura-stake-boosted-by-nationwide-fund-advisors.html.
Kura Oncology, Inc. (KURA) opened at $15.95 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48. Kura Oncology, Inc. has a 1-year low of $4.72 and a 1-year high of $16.75.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). equities research analysts expect that Kura Oncology, Inc. will post -1.45 EPS for the current year.
A number of equities research analysts recently commented on the stock. Zacks Investment Research raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, August 10th. Citigroup Inc. set a $13.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a research note on Tuesday, August 8th. Leerink Swann reissued an “outperform” rating and issued a $18.00 price objective (up from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. ValuEngine raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Finally, Cann restated a “buy” rating on shares of Kura Oncology in a report on Wednesday, November 8th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Kura Oncology presently has an average rating of “Buy” and a consensus price target of $17.20.
Kura Oncology Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA).
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.